News

October 15, 2024

Synedgen Receives Contract from BARDA to Develop MIIST305 as a Medical Countermeasure for Gastrointestinal Acute Radiation Syndrome
Read More

September 24, 2024

Synedgen Adds Dr. Hal J. Oien to its Board of Directors
Read More

April 25, 2024

Synedgen Completes IND-Enabling Studies for Two Parallel Programs for Lead Asset MIIST305
Read More